Therapeutic Solutions International Continues Parallel Development of COPD Program in Conjunction with Pivotal Clinical Trial in COVID-19
Therapeutic Solutions International announced today new data demonstrating enhancement of therapeutic activities of the JadiCell™ through induction of a specific cell type called “Myeloid Derived Progenitor Cells”.
In a series of experiments, mice were treated with JadiCells, Myeloid Derived Suppressor Cells, and a combination of the two. It was found that the combination possessed superior ability to reduce lung damage and stimulate pulmonary regeneration. Additionally, administration of the FDA cleared drug Leukine was demonstrated to naturally increase levels of Myeloid Derived Suppressor cells and enhance activity of the JadiCells.
“As a medical doctor that routinely sees the devastation caused by COPD, I am extremely excited about the possibility of curing this disease” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “But in order to even begin talking about cures, we need to realize that a pathology as complex as COPD will not be cured by a 'magic bullet.' Therefore, we are always searching for new ways to continually increase the efficacy of our approaches.”
The Company recently filed an Investigational New Drug application for using its Phase III stem cells, called JadiCells, for treatment of COPD1.
“These recent data are a result of our multidisciplinary approach to chronic diseases. Since there is an immunological mechanism at play here, we are currently in discussion with several immunotherapy stakeholders for collaborations and partnerships” said Timothy Dixon, President and CEO of the Company and co-inventor of the patent.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005565/en/
Contacts
Timothy G. Dixon
ir@tsoimail.com
